Special Edition: Understanding Chronic Kidney Disease in People with Diabetes — Epidemiology, Pathophysiology, and Detection

Diabetes Core Update | March 12, 2026 | Hosts: Dr. Neil Skolnik & Dr. Holly Kramer

Episode Overview

This special edition of the Diabetes Core Update explores the intersection of chronic kidney disease (CKD) and diabetes. The discussion centers around the prevalence, underlying mechanisms, risk factors, and—most critically—how clinicians can most effectively detect CKD early in patients with diabetes. The episode emphasizes recent advances in treatment that can dramatically improve patient outcomes, but underscores the foundational necessity of early diagnosis and systematic screening.

Key Discussion Points & Insights

The Urgency of Early CKD Detection in Diabetes

• Only about 20% of people with kidney disease know they have it ([01:46]).
  • “If we can get people diagnosed earlier and treated, we can really do kidney failure. And kidney failure is hugely costly to our health system.” – Dr. Holly Kramer [01:49]
• The US spends ~$150 billion annually on dialysis and CKD.
  • Early detection isn’t just medically crucial, it’s economically imperative.

Personal Motivation & Historical Perspective

• Dr. Kramer’s path to nephrology was influenced by her mother, a dialysis nurse in the 1970s, illuminating the progression from home dialysis to today’s prevention focus ([02:49]).
  • Memorable anecdote: Accompanying her mother to homes fitted with “gigantic dialysis machines” on blue shag carpet.
  • “Her hope was that I would become a nephrologist to prevent people from getting kidney failure in the first place, because back then she was very prescient.” – Dr. Holly Kramer [03:32]

Epidemiology: Who Gets CKD?

• About 40% of people with diabetes will develop kidney disease in their lifetime ([05:32]).
  • Type 1 diabetes: Begin screening five years after diagnosis; damage typically detectable 10–15 years after onset.
  • Type 2 diabetes: Screen at diagnosis, due to uncertain onset and high prevalence.
  • Obesity: No clear formal recommendations; risk becomes direct (beyond mediation by diabetes/hypertension) at BMI > 40–45 due to compression/ischemia ([06:38]).
    • “Most of the kidney disease from obesity is really mediated by its effects on metabolism: diabetes and hypertension.” – Dr. Holly Kramer [07:13]
• Additional risk factors: Cardiovascular disease, family history (especially dialysis), low nephron number (premature birth), prior nephron injury (e.g., chemotherapy, nephrectomy) ([08:11]).

Pathophysiology: How Diabetes Causes Kidney Damage

• Nephrons (approx. 1 million per kidney) filter blood; in diabetes, high glucose means more is reabsorbed in the proximal tubule via sodium-glucose co-transporters.
• This leads to less sodium at the macula densa (the “thermostat”), causing afferent arteriole dilation and glomerular hyperfiltration.
  • “You see a creatinine of 0.6 and you’re like, oh, my patient’s doing fine. They’re not. They are hyper filtrating.” – Dr. Holly Kramer [13:08]
• Hyperfiltration correlates with high A1C; inflammation and “advanced glycation end products” (AGEs) drive scar tissue/fibrosis, causing nephron loss.
• Classic diabetic damage: Scar tissue formation, loss of functional nephrons, and eventual GFR decline ([11:03–14:47]).

CKD Screening: What, When, and How?

• Serum creatinine & eGFR:
  • Obtain at least annually.
  • GFR < 60 is concerning, though age must be considered ([15:21]).
• Urine albumin-to-creatinine ratio (UACR):
  • “Where we are really losing out is the urine albumin to creatinine ratio...about 95% of people with diabetes get their creatinine measured every year...but the urine albumin to creatinine ratio, every health system just has so many different ways to measure it.” – Dr. Holly Kramer [04:23]
  • UACR is the earliest marker of nephron stress and kidney disease.
  • UACR > 30 mg/g: Action threshold, even if GFR is normal ([15:21]).
• Screening adherence is poor: Only 20–40% of people with diabetes get their UACR measured annually ([17:56]).
  • Terminology confusion (“microalbuminuria,” etc.) has contributed to underuse and misunderstanding.

UACR: Interpretation & Next Steps

• UACR is a sensitive but non-specific test—numerous conditions (infections, uncontrolled BP, acute illness) can cause transient elevations.
• Key practice point: If elevated, repeat the test in 2 months before confirming diagnosis ([21:25]).
  • “So if you find a positive test, always repeat it like in two months. The urine albumin to creatinine ratio is really noisy. It's influenced by illness...you should not give a diagnosis of moderate or severely increased urine albumin excretion unless you do show that it's persistent.” – Dr. Holly Kramer [21:29]
• Understanding UACR values: “Bad things happen in threes” mnemonic:
  • Normal: <3 mg/g
  • Moderately increased: ≥30 mg/g
  • Severely increased: ≥300 mg/g ([24:10])

The Pillars of Care: Responding to Abnormal Screening Results

• Core interventions for CKD in diabetes:
  • Blood pressure control (ACEi/ARB for those with elevated UACR)
  • Medical nutrition therapy
  • SGLT2 inhibitors
  • Non-steroidal mineralocorticoid receptor antagonists
  • GLP-1 agonists (possibly with GIP)
  • Weight loss, however achieved
  • “The kidneys love weight loss.” – Dr. Holly Kramer [23:34]
• “There used to be not much you could do and now we actually have pillars of care.” – Dr. Neal Skolnik [22:56]
• Note: Deep dive into treatment will be covered in future podcasts.

Notable Quotes & Memorable Moments

• On Patient Awareness and the Need for Early Detection
  • “Only 20% of people with kidney disease are aware that they have it.” – Dr. Holly Kramer [01:49]
• Historical Context
  • “I would skip school and go with [my mom] to houses with a lot of blue shag carpet and a gigantic dialysis machine.” – Dr. Holly Kramer [02:56]
• On Pathophysiology
  • “You see a creatinine of 0.6 and you're like, oh, my patient's doing fine. They're not. They are hyper filtrating.” – Dr. Holly Kramer [13:08]
• On Optimizing Screening
  • “The first thing you'll see down that stressed nephron is the albumin in the urine goes up. So that's why measuring that urine albumin to creatinine ratio, that's the earliest way that you can find kidney disease.” – Dr. Holly Kramer [16:37]
• Practical Mnemonic for UACR
  • “Bad things happen in threes... It's 3 milligrams per gram...30 mg/g is the moderately increased, and 300 mg/g severely increased urinary albumin-creatinine ratios.” – Dr. Holly Kramer [24:10]

Important Timestamps

• [01:46–02:30]: Scope of CKD, cost, need for early diagnosis
• [02:49–04:47]: Dr. Kramer’s background, rise of CKD with diabetes/obesity epidemics
• [05:32–08:11]: Epidemiology, risk factors, impact of obesity and metabolic disease
• [11:03–14:47]: Pathophysiology of diabetic kidney disease
• [15:21–17:18]: How/when to screen for CKD in diabetes
• [17:56–20:20]: Real-world rates of UACR testing, barriers
• [21:25–22:18]: Sensitivity/specificity and need for repeat UACR testing
• [22:56–23:45]: Brief overview of new therapeutic pillars
• [24:10–25:23]: UACR interpretation and memorable mnemonics

Summary Table: CKD Screening in Diabetes

| Risk Population | When to Screen | Key Tests | UACR Action Threshold | Follow-up | |-------------------------|-------------------|-----------------------|-----------------------|-------------------------------| | Type 1 Diabetes | 5+ years dx | eGFR, UACR | >30 mg/g | Repeat UACR in 2 months if high| | Type 2 Diabetes | At diagnosis | eGFR, UACR | >30 mg/g | Repeat and confirm | | Obesity (esp. BMI >40) | No guidelines | Consider screening | -- | -- | | Other risk factors | Clinical judgment | eGFR, UACR as above | >30 mg/g | -- |

Take-Home Messages

• Screen for CKD annually in all people with diabetes—but especially ensure UACR is included.
• Elevated UACR is the earliest indicator of kidney stress—repeat to confirm before acting.
• Modern therapeutics can slow CKD progression, but detection is essential.
• Use the “3–30–300” mnemonic for interpreting UACR results.
• Leverage EMR reminders and clinical education to close the UACR testing gap.

Closing Remark

“Thank you for joining us on this special edition of Diabetes Core Update, discussing CKD in people with diabetes... We are going to do a deep dive on treatment in a future episode, so tune back in.” – Dr. Neal Skolnik [25:44]